Actualizado 06/12/2010 14:16
- Comunicado -

Follow-Up Results from Study Comparing SPRYCEL(R) (dasatinib) to Imatinib in First-Line Treatment of Adults with Ph+ CP-

[6] American Cancer Society Web site. "Can Chronic Myeloid Leukemia Be Prevented?" Available at: http://nccu.cancer.org/docroot/CRI/conte... Accessed on November 4, 2010.

(Due to the length of the above URLs, it may be necessary to copy and paste the above hyperlinks into your Internet browser's URL address field. Remove the spaces if they are present.)

CONTACT: Contacts: Bristol-Myers Squibb, Media: Sarah Koenig,Bristol-Myers Squibb, +1-609-252-4145, sarah.koenig@bms.com; European Media Contact: Elzbieta Zawislak, Bristol-Myers Squibb, +33-615-523580, elzbieta.zawislak@bms.com;Otsuka, US: David Caruba, Otsuka America Pharmaceutical Inc., +1-609-524-6798, david.caruba@otsuka-us.com; Japan: Masamitsu Kitada, Otsuka Pharmaceutical Co., Ltd., kitadams@otsuka.jp